Join your Indiana peers for a day focused exclusively on perinatal substance use and its significant impact on families, caregivers, and communities. We are honored to welcome some of the foremost experts from around the country to discuss innovative, supportive care approaches designed to improve outcomes for families and avoid staff burnout for those charged with caring for this vulnerable population.
CMOs, CNOs, maternal/child teams, neonatal teams, patient safety officers, risk managers, quality leaders, nursing caregivers and managers, case managers, care transition managers, social workers, and others responsible for patient safety. Teams are encouraged to attend.
At the end of the day, attendees will be able to:
- Apply practical strategies in their facilities to respond to the opiate epidemic within the maternal/child population
- Engage with local partners to identify strategies to address the perinatal substance use crisis
- Understand how a statewide approach to perinatal substance use can lead to infrastructure development for improved outcomes
FORUM Events Center | 11313 USA Pkwy, Fishers, IN 46037 * This event is in-person only. A virtual option will not be available.
Thursday, Sept. 14, 2023 | 9 a.m. - 3:30 p.m. ET
$50 Registration Fee * If this registration is cancelled on or before Aug. 30, a $20 fee will be retained. Refunds are not available after Aug. 30, but substitutions are allowed onsite or in advance by notifying Molly Kelly
Reach out to Molly Kelly
, Member Engagement and Marketing Coordinator at IHA.
Ira Chasnoff, MD - President of NTI Upstream & Professor of Clinical Pediatrics at the University of Illinois College of Medicine
The Mystery of Risk: Drugs, Alcohol, Pregnancy, and the Vulnerable Child
Children prenatally exposed to alcohol and drugs face increasing neurodevelopmental challenges as they grow and develop. These challenges translate into behavioral and learning difficulties in the classroom and in the home. This program will present an evidence-based approach to screening pregnant women for risk of substance misuse, explore the biological and environmental factors that impact pregnancy and the ultimate development of substance-exposed children, and provide a conceptual framework for assessing the behavior and learning difficulties of children affected by prenatal substance exposure.
At the completion of this session the participant will be able to:
- Describe and compare screening and brief intervention strategies for pregnant women.
- Discuss the impact of prenatal substance exposure on neonatal outcome.
- Name four criteria for diagnosis within Fetal Alcohol Spectrum Disorders.
- Analyze the impact of prenatal substance exposure on the long term cognitive and behavioral development of the child.
Ira J. Chasnoff, M.D., an award-winning author, researcher and lecturer, is president of NTI Upstream and a Professor of Clinical Pediatrics at the University of Illinois College of Medicine in Chicago. He is one of the nation's leading researchers in the field of child development and the effects of environmental factors on the developmental trajectory of children and adolescents. Dr. Chasnoff’s work encompasses community approaches to the integration of behavioral health services into primary health care, the schools, and the other multiple systems that serve children and families. Dr. Chasnoff has served several U.S. presidential administrations on committees and commissions dedicated to organizing and coordinating services for children and families across the nation and developing policies and procedures for addressing the needs of children at risk from prenatal and postnatal trauma. He also has worked with a wide range of States across the nation and internationally in developing universal outreach and early intervention programs for children and families affected by trauma or substance abuse.
Dr. Chasnoff received his medical degree from the University of Texas Health Science Center at San Antonio, which in 1991 awarded him its first Distinguished Alumnus Award. He is the author of numerous research articles regarding the long-term cognitive, behavioral, and learning outcomes of high-risk children, and his article on racial and social class bias in the health care system has been cited as a landmark study by the American College of Obstetricians and Gynecologists. Dr. Chasnoff has authored 15 books, which have received numerous awards and one of which has been recognized by The Hague International Court. Dr. Chasnoff's books explore the biological and environmental factors that impact the ultimate development of high-risk children and presents practical strategies for helping children reach their full potential at home and in the classroom. His newest book, Guided Growth, has received international acclaim for its in-depth discussion of educational and behavioral interventions for children and teens with Fetal Alcohol Spectrum Disorders and early trauma. Dr. Chasnoff has been a regular contributor to Psychology Today, writing about high-risk children and their families. The recipient of several awards for his work with women, children, and families, Dr. Chasnoff for several years has been selected by a poll of physicians across the nation for listing in America's Best Doctors, cited for his ability to translate complex medical and psychosocial issues into relevant policy that guides the delivery of quality services. Dr. Chasnoff has been active in establishing comprehensive family intervention programs for children in Australia, Denmark, Portugal, Canada, Vietnam, the former Soviet Union, and across the United States and has lectured on this topic around the world.
Jerome Adams, MD, MPH, FASA - 20th U.S. Surgeon General & Executive Director of Health Equity Initiatives, Purdue University
Fireside Chat with Dr. Rahul Gupta
Dr. Jerome Adams was appointed as a Presidential Fellow and the Executive Director of Purdue's Health Equity Initiatives on October 1, 2021. He is also a Distinguished Professor of Practice in the departments of Pharmacy Practice and Public Health.
As the 20th U.S. Surgeon General and a prior member of the President's Coronavirus task force, Dr. Adams has been at the forefront of America's most pressing health challenges. A regular communicator via tv, radio, and in print, Dr. Adams is an expert not just in the science, but also in communicating the science to the lay public, and making it relevant to various audiences.
Dr. Adams is a licensed anesthesiologist with a master's degree in public health, and ran the Indiana State Department of Health prior to becoming Surgeon General. In the State Health Commissioner role he managed a $350 million dollar budget and over 1000 employees, and led Indiana’s response to Ebola, Zika, and HIV crises. Notably, Dr. Adams helped convince the Governor and State Legislature to legalize syringe service programs in the state, and to prioritize $13 million in funding to combat infant mortality. As Surgeon General, Dr. Adams was the operational head of the 6,000-person Public Health Service Commissioned Corps, and oversaw responses to 3 back to back category 5 hurricanes, and to a once in a century pandemic.
In addition to his recent COVID19 work, Dr. Adams has partnered with and assisted organizations as they navigate the opioid epidemic, maternal health, rising rates of chronic disease, the impacts of rising suicide rates in our Nation, and how businesses can become better stewards and stakeholders in promoting community health
His lifelong commitment to educating the next generation of physicians and policymakers has led him to hold academic appointments throughout his career including as a clinical professor in the Department of Medicine at Georgetown University School of Medicine and as visiting faculty at the Harvard University T.H. Chan School of Public Health. Additionally, his passion for global health led him to join the March of Dimes as Chief Medical and Health Officer and Senior Vice President, where he provided strategic oversight for the organization’s domestic and global medical and public health efforts. Rahul Gupta, MD, MPH, MBA, FACP - White House Director of the Office of National Drug Control Policy
Fireside Chat with Dr. Jerome Adams
Dr. Rahul Gupta is the first medical doctor to serve as the Director of National Drug Control Policy and lead the Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President. ONDCP coordinates the nation's $43 billion drug budget and federal policies, including prevention, harm reduction, treatment, recovery support, and supply reduction.
Through his work as a physician, a state and local leader, an educator, and a senior leader of a national nonprofit organization, Dr. Gupta has dedicated his career to improving public health and public safety.
A board-certified internist, Dr. Gupta has been a practicing primary care physician for more than 25 years, and has served in private practice and public health in towns as small as 1,900 residents and cities as large as 25 million. He has served as a local public health official and as the West Virginia Health Commissioner under two governors, where he brought together public health, law enforcement, healthcare, faith-based, business, and other community partners to solve local problems in novel and innovative ways. As the state's Chief Health Officer, he led the opioid crisis response and launched a number of pioneering public health initiatives, including the Neonatal Abstinence Syndrome Birthscore program to identify high-risk infants, and the groundbreaking statewide Social Autopsy, which examined the lives of overdose victims to determine the factors that led to their deaths and what services could have prevented their deaths. This led the state to expand access to naloxone as well as treatment services including those for incarcerated individuals in order to save lives and help people transition back into society. He supported the expansion of harm reduction programs to more than a dozen sites across the state. He was also instrumental in expanding state-of the-art, comprehensive and integrative medical and behavioral health programs for pregnant and postpartum women.
Dr. Gupta is a national and global thought leader and a driver of innovative public policies who practices what he preaches. He is a buprenorphine-waivered practitioner, providing medication-assisted treatment for people with opioid use disorder. He has been recognized for his career of public service by the American Medical Association, the American Public Health Association, and by Governing Magazine, which named him their Public Health Official of the Year in 2018. Additionally, the Pulitzer Prize-winning Charleston Gazette-Mail named him as one of its West Virginians of the Year in 2017 for his service to the state.
Camila Arnaudo, MD - Addiction Psychiatrist & Interim Vice Chair of Education, IU School of Medicine Dept of Psychiatry
How to Use Indiana CHAMP Program in Your Practice: Case Study of Bipolar Disorder in Perinatal Period
Camila Arnaudo, M.D. is a perinatal addiction psychiatrist whose work focuses on mental health and addictive illnesses in pregnant and postpartum people with a particular focus on increasing equity and accessibility to quality care. She is the recently named interim vice chair of education for the psychiatry department of Indiana University School of Medicine.
She is co-medical director of the Indiana CHAMP (Consultations for Healthcare providers in Addiction, Mental Health, and Perinatal Psychiatry) Program, which a statewide program providing consultations to frontline providers on treatment of psychiatric illness. She is medical director of the Addictions Treatment Recovery Center (ATRC) at IU Health in Bloomington, and a member of the Indiana Maternal Mortality Review Committee (MMRC).
She completed medical school at the University of Maryland School of Medicine in Baltimore, Maryland, and residency in psychiatry at the Harvard Longwood Psychiatry Training Program in Boston, Massachusetts. Her fellowship in addictions psychiatry is from Indiana University School of Medicine in Indianapolis.